Disease-modifying therapies slow down the progression of multiple sclerosis. Beta interferon drugs reduce MS attacks by altering the immune response. Copaxone and Glatopa mimic a protein in myelin to ...

The US Food and Drug Administration (FDA) has approved a higher-dose, lower-frequency regimen for glatiramer acetate (Copaxone, Teva Pharmaceutical Industries) in the treatment of relapsing-remitting ...

This story is free to read because readers choose to support LAist. If you find value in independent local reporting, make a donation to power our newsroom today. Listen 3:38 About 400,000 Americans ...

There is currently no cure for Multiple Sclerosis (MS). Patients rarely do well with no therapy at all, and it is generally recommended that patients with a confident diagnosis of MS begin treatment ...